

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael Caplan

NON DB SOOR

Serial No.:

09/247,406

Art Unit:

Filed:

February 10, 1999

Examiner:

TECH CENTER 1600/2900

For:

METHOD FOR ALTERING UNDESIRABLE IMMUNE RESPONSES TO

POLYPEPTIDES

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) page of Form PTO-1449, copies of the documents cited therein, and a copy of the International Search Report, mailed September 19, 2000, in the corresponding PCT application PCT/US00/03448.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

U.S.S.N.:

09/247,406

Filed:

February 10, 1999

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Foreign Documents

<u>Number</u>	Publication Date	<u>Patentee</u>	Country
WO 97/33910 A1	09-18-1997	The Rockefeller University	PCT
WO 98/06861 A2	02-19-1998	Agrivax Incorporated	PCT

Publications

SMITH & CHAPMAN, "Localization of antigenic sites on Der p 2 using oligonucleotidedirected mutagenesis targeted to predicted surface residues," Clinical and Experimental Allergy 27:593-99 (1997).

WIEDEMANN, et al., "Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody," J Biol Chem 271(47):29915-21 (1996).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: November 2, 2000

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 W. Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax)

U.S.S.N.:

09/247,406

Filed:

February 10, 1999 SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT





TECH CENTER 1 3000

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

November 2, 2000

3



nd Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid GM8 control number Substitute for form 1449A/PTO Complete if Known **Application Number** 09/247,406 **INFORMATION DISCLOSURE** MOV 0.9 2000 STATEMENT BY APPLICANT use as many sheets as necessary) February 10, 1999 CH CENTER 1900 2900 Filing Date First Named Inventor Michael Caplan NOV 0 6 2000 Group Art Unit 1627 Examiner Name T. Wessendorf 2 Attorney Docket Number **HS 105 U.S. PATENT DOCUMENTS** Name of Patentee or Applicant **Date of Cited** Pages, Columns, Lines, Where Relevant Examiner Cite **US Patent Document** of Cited Document Document Passages or Relevant Figures Appear Initials* No. MM-DD-YYYY Number Kind Code (if known) **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Name of Patentee or Date of Publication Pages, Columns, Lines, Where Examiner Cite Applicant of Cited Document of Cited Document Relevant Passages or Relevant Initials* No.1 MM-DD-YYYY Figures Appear Kind Code⁵ Office.3 Number⁴ (if known) 97/33910 The Rockefeller University 09-18-1997 wo Α1 98/06861 02-19-1998 wo Agrivax Incorporated

Examine	 Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

¹ Unique citation designation number 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant to place a check mark here if English language Translation is attached.



Under the Paperwo	rk Reductio	n Act of 1995, no persons a	re required to respond to a collection of informat	ion unless it contains a valid OMB control number		
	Substit	ute for form 14	49A/PTO		Complete if Known	RECEIVED
STATEMENT BY APPLICANT O I P (use a many sheets as necessary)		Application Number	09/247,406	AUM 03 5000		
				TECH CENTER 1600/		
/		%		Filing Date	February 10, 199	9
I No	V 0 -	1		First Named Inventor	Michael Caplan	
B	' " "	2000		Group Art Unit	1627	
172				Examiner Name	T. Wessendorf	
Sheet &	2	of of	2	Attorney Docket Number	HS 105	
	ADEN	ARIE	OTHER ART	NON PATENT LITERATURE DO	CLIMENTS	
Cuaminaria	Cite				rticle (when appropriate), title of the	T ²
Examiner's Initials*	No.1	i	item (book, magazine, journal,		late, page(s), volume-issue number(s	
			•	ntigenic sites on Der p 2 using on the state of the state	oligonucleotide-directed mutage 3-99 (1997).	nesis targeted
			et al., "Molecular and struiol Chem 271(47):29915-		birch profilin epitope defined b	y a monoclonal
			440-			

Examiner's	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1294082v1

HS 105

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant to place a check mark here if English language Translation is attached.